Abstract
Immune checkpoint inhibitors have been increasingly used in patients with various cancers. Despite favourable oncological outcomes these treatments have also been associated with immune-related adverse events. Neurological irAE are rare but potentially severe and neuromuscular complications are the most common. This is a new group of neurologic complications of systemic anticancer therapies, often responsive to immune-modulating therapies. Early recognition and treatment are crucial for timely improvement of functional outcome and requires a multidisciplinary approach.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Cell Cycle Checkpoints / immunology
-
Humans
-
Immunotherapy / adverse effects*
-
Immunotherapy / methods
-
Myasthenia Gravis / chemically induced
-
Myasthenia Gravis / diagnosis
-
Myasthenia Gravis / therapy
-
Myositis / chemically induced
-
Myositis / diagnosis
-
Myositis / therapy
-
Neoplasms / drug therapy*
-
Neuromuscular Diseases / chemically induced*
-
Neuromuscular Diseases / diagnosis
-
Neuromuscular Diseases / epidemiology
-
Neuromuscular Diseases / therapy
-
Peripheral Nervous System Diseases / chemically induced
-
Peripheral Nervous System Diseases / diagnosis
-
Peripheral Nervous System Diseases / therapy
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
Substances
-
Protein Kinase Inhibitors